Following its initial lawsuit last month, Merck has now requested that a federal judge rule on its Inflation Reduction Act case against the Biden administration without a trial.
Tag Archive for: Merck
The Inflation Reduction Act could put an end to blockbuster runs like that of Merck’s Keytruda. In the meantime, the drug keeps picking up more indications and positive clinical results.
Merck had requested the regulator’s Committee for Medicinal Products for Human Use (CHMP) to re-examine the application for molnupiravir, which is sold under the brand Lagevrio in several countries, after CHMP advised against its market authorization in February.
Merck now faces a raft of lawsuits alleging it knew from its early research that the drug could impact the brain and that it minimized the potential for psychiatric problems in statements to regulators.
The company teased data for efinopegdutide, a GLP-1/glucagon receptor co-agonist, in nonalcoholic steatohepatitis compared to Novo Nordisk’s semaglutide, which is not yet approved for NASH.
Merck & Co said it sued the U.S. government on Tuesday, seeking an injunction of the drug price negotiation program contained in the Inflation Reduction Act (IRA), which it argues violates the Fifth and First Amendments to the U.S. Constitution.
The American Society of Clinical Oncology 2023 annual meeting kicked off Friday in Chicago, and BioSpace’s Greg Slabodkin spoke with leading biopharma analysts about the most-anticipated ASCO abstracts.
Adding an experimental mRNA-based vaccine from Moderna and Merck reduced the risk that the most deadly skin cancer would spread by 65% over treatment with an immunotherapy alone in a midstage trial, the companies reported today.
The company will present data at the oncology meeting showing the drug’s significant survival benefit in patients with advanced renal cancer and recurrent, persistent and metastatic cervical cancer.
Today AstraZeneca announced that a combination of its cancer drugs Imfinzi and Lynparza when added to platinum-based chemotherapy showed positive results in a late-stage trial in patients with advanced or recurrent endometrial cancer.